You are here: Industry Insights > CStone

News List

CStone receives IND approval in China for avapritinib study biospectrumasia
April 16, 2019
This is a stand-alone bridging trial consisting of a Phase I dose-escalation study and Phase II dose-expansion study, with the aim of determining the safety……
CStone received IND approval in China for HDAC6 inhibitor CS3003 en-cphi.cn
March 13, 2019
Cstone announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical trial in China.
CStone Pharmaceuticals appoints Richard Yeh as CFO biospectrumasia
July 25, 2018
Extensive Track Record in Pharmaceutical Financial Management will Solidify CStone's Leading Position Among Innovative Biopharmaceutical Companies in China.
CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia prnasia
January 02, 2018
CStone Pharmaceuticals (Suzhou) Co., Ltd. today announced that it has submitted an Investigational New Drug (IND) application to the Human Research Ethics Committee at Ashford Cancer Center in Australia
CStone files CS1003, an anti-PD-1 antibody, for clinical trial approval in Australia prnasia
December 29, 2017
CStone announced today that it has formally applied for clinical trial approval of the anti-PD-1 monoclonal antibody (mAb) candidate submitted to the Human Research Ethics Committee at the Scientia Clinical Research Center in Australia CS1003.
Opening Ceremony of CStone Pharmaceuticals' Suzhou Translational Medicine Research Center and an ass prnasia
November 03, 2017
CStone Suzhou Translational Medicine Research Center (TMRC) was officially launched in Suzhou Industrial Park on October 28, 2017.

Previous page 1 2 3 4 5 Next page